Patient P-01402

Synthetic patientNBL-101 · Day 118 · 35–44 · M · baseline S04Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Improving

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

60%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S04
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 63 GI symptom burden −29% vs expected — GI Support Protocol GI-04
Day 63 ME-01 recommended — Monitoring Escalation ME-01
Day 64 Patient accepted — Started ME-01 in the companion
Day 67 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 69 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days

Toxicity+8
Inflammatory activity+7
GI instability-4
Treatment adherence+2

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
GI Support Protocol GI-04Day 54
Result: symptom burden −29%
Monitoring Escalation ME-01Day 63
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

64%

probability of meaningful tolerance improvement

284 similar trajectories
81% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

53.6/100

stable · +0.3 vs previous 14 d

Toxicity

Blood

52.3/100

improving · -4.6 vs previous 14 d

Sleep quality

Wearable

17.5/100

worsening · -2.1 vs previous 14 d

Energy level

Daily log

3.1/10

stable · +0.0 vs previous 14 d

Stress level

Daily log

6.9/10

stable · -0.2 vs previous 14 d

Steps

Wearable

459

stable · -17 vs previous 14 d

Adherence

Companion

49 %

worsening · -3.5 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 22 from the failing basin, 65 from restoration.

Would help

SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 64%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 64%

Would not help

NP-02 Dietary Support Protocol
already tried, no meaningful change
Keep fat low
GI +2.9 next day on high-intake days · n 21
Keep histamine low
GI +2.2 next day on high-intake days · n 18

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+2.9detractor · 95%
Histamine load
+2.2detractor · 77%
Spicy / capsaicin
+1.3no signal · 45%
Simple carbohydrates
+1.1no signal · 33%
Alcohol
+1.1no signal · 35%
Insoluble fibre
+0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 54 and rising
- WearableSleep 6.0 h, below personal baseline
Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 58
- WearableHRV 24 ms, trending down
Autonomic recovery ↑65
- WearableResting HR 86 bpm
- Wearable459 steps/day
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 52

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3.2 · butyrate capacity 33/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 6.6 h
Steps: 1,038
Resting HR: 84 bpm

Daily log: GI score 54, nutritional resilience 39, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01802	49%	S20	NP-02	improved	42
P-01349	47%	S14	GI-04	improved	38
P-01462	47%	S14	NP-02	improved	47
P-01810	47%	S05	NP-02	improved	43
P-01429	46%	S09	GI-04	improved	45
P-01433	46%	S14	GI-04	improved	48
P-01409	45%	S14	SC-12	improved	41
P-01431	45%	S14	GI-04	improved	41
P-01496	45%	S14	SC-12	improved	46
P-01692	45%	S14	NP-02	improved	49
P-01406	44%	S18	GI-04	improved	50
P-01447	44%	S15	GI-04	improved	44